Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 109

Results For "SSI"

5562 News Found

Feinstein Institutes awarded $3.37 million grant to boost first responder mental health
R&D | December 01, 2025

Feinstein Institutes awarded $3.37 million grant to boost first responder mental health

The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas


Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection
R&D | December 01, 2025

Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection

Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes


GE HealthCare launches game-changing StarGuide GX for precision nuclear medicine
Digitisation | December 01, 2025

GE HealthCare launches game-changing StarGuide GX for precision nuclear medicine

StarGuide GX delivers ultra-high sensitivity and high-resolution imaging, enabling fast, confident diagnostics


Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay
Drug Approval | November 30, 2025

Ascendis Pharma’s FDA review of Achondroplasia drug gets 3-month delay

The FDA has classified recent submissions as a major amendment pushing the approval to its NDA for TransCon CNP back three months to February 28, 2026


MHRA clears inavolisib, offering new option for returning breast cancer
News | November 30, 2025

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy


InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China
Clinical Trials | November 30, 2025

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders


Amrutanjan re-launches its iconic yellow balm
News | November 29, 2025

Amrutanjan re-launches its iconic yellow balm

Amrutanjan is also rolling out its new campaign, 'Har Dard Mitaye'